Print

Main Results of the Full Phase I/II Study of PCI Biotech's Amphinex(R)  
6/27/2011 9:55:53 AM

OSLO, Norway--(BUSINESS WIRE)--PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex® in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin.
//-->